StreetInsider.com News Articles

Form SCHEDULE 13G/A Verastem, Inc. Filed by: ARMISTICE CAPITAL, LLC

Fri, 14 Aug 2026 10:29:00 -0400

si-local-file:///var/storage/secattach/20260814/26926449.html

Form SCHEDULE 13G/A Verastem, Inc. Filed by: ARMISTICE CAPITAL, LLC

Fri, 14 Aug 2026 10:29:00 -0400

si-local-file:///var/storage/secattach/20260814/26926449.html

Verastem (VSTM) PT Lowered to $13 at Mizuho

Tue, 11 Aug 2026 06:36:33 -0400

(Updated - August 11, 2026 6:36 AM EDT)

Mizuho analyst Graig Suvannavejh lowered the price target on Verastem (NASDAQ: VSTM) to $13.00 (from $14.00) while maintaining a Outperform rating.

The analyst commented: "VSTM reported 2Q26 results last week, with Avmapki Fakzynja Co-Pack/AFC revenue of $25.1mn (+34% q/q) beating Mizuho/consensus of $23.4mn/$22.8mn — importantly marking a healthy rebound vs. a weak 1Q result that spooked investors and sent the stock tumbling. Beyond the strong AFC number, other key 2Q updates included: (1) a new $75mn royalty (i.e. non-dilutive) financing and also a surprise Copiktra-related $15mn sales milestone payment received from partner Secura Bio,

Verastem (VSTM) PT Lowered to $13 at Mizuho

Tue, 11 Aug 2026 06:36:33 -0400

(Updated - August 11, 2026 6:36 AM EDT)

Mizuho analyst Graig Suvannavejh lowered the price target on Verastem (NASDAQ: VSTM) to $13.00 (from $14.00) while maintaining a Outperform rating.

Form SCHEDULE 13G Verastem, Inc. Filed by: STATE STREET CORP

Fri, 07 Aug 2026 11:10:00 -0400

si-local-file:///var/storage/secattach/20260807/26889320.html

Form SCHEDULE 13G Verastem, Inc. Filed by: STATE STREET CORP

Fri, 07 Aug 2026 11:10:00 -0400

si-local-file:///var/storage/secattach/20260807/26889320.html

Form 8-K Verastem, Inc. For: Aug 06

Fri, 07 Aug 2026 06:19:00 -0400

si-local-file:///var/storage/secattach/20260807/26887076.html

Form 8-K Verastem, Inc. For: Aug 06

Fri, 07 Aug 2026 06:19:00 -0400

si-local-file:///var/storage/secattach/20260807/26887076.html

Form 8-K Verastem, Inc. For: Aug 06

Thu, 06 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260806/26884671.html

Form 8-K Verastem, Inc. For: Aug 06

Thu, 06 Aug 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260806/26884671.html

Verastem Oncology (VSTM) Tops Q2 EPS by 12c

Thu, 06 Aug 2026 16:21:37 -0400

Verastem Oncology (NASDAQ: VSTM) reported Q2 EPS of ($0.31), $0.12 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $40.07 million versus the consensus estimate of $23.09 million.

For earnings history and earnings-related data on Verastem Oncology (VSTM) click here.

Form 10-Q Verastem, Inc. For: Jun 30

Thu, 06 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260806/26884141.html

Form 10-Q Verastem, Inc. For: Jun 30

Thu, 06 Aug 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260806/26884141.html

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Thu, 06 Aug 2026 16:01:00 -0400

AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $25.1 million

First patients dosed in all three TARGET-D Phase 2 registration-directed clinical trials evaluating VS-7375 across 2L PDAC, 2L/3L NSCLC, and 2L+ CRC

Updated clinical data for VS-7375 across pancreatic, lung, and colorectal cancers expected in October

Entered into a non-dilutive royalty financing agreement with Oberland Capital providing up to $75 million in cash, including $50 million at closing

Ended Q2 2026 with $136.4 million in cash, cash equivalents, and investments; proforma cash of $201.4M with Oberland and COPIKTRA sales milestone ($15M), combined with expected product revenue and future tranche from

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Thu, 06 Aug 2026 16:01:00 -0400

AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $25.1 million
First patients dosed in all three TARGET-D Phase 2 registration-directed clinical trials evaluating VS-7375 across 2L PDAC, 2L/3L NSCLC, and 2L+ CRC
Updated clinical data for VS-7375 across pancreatic, lung, and colorectal cancers expected in October
Entered into a non-dilutive royalty financing agreement with Oberland Capital providing up to $75 million in cash, including $50 million at closing
Ended Q2 2026 with $136.4 million in cash, cash equivalents, and investments; proforma cash of $201.4M with Oberland and COPIKTRA sales milestone ($15M), combined with expected product revenue and future tranche from

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Thu, 06 Aug 2026 16:01:00 -0400

AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $25.1 million
First patients dosed in all three TARGET-D Phase 2 registration-directed clinical trials evaluating VS-7375 across 2L PDAC, 2L/3L NSCLC, and 2L+ CRC
Updated clinical data for VS-7375 across pancreatic, lung, and colorectal cancers expected in October
Entered into a non-dilutive royalty financing agreement with Oberland Capital providing up to $75 million in cash, including $50 million at closing
Ended Q2 2026 with $136.4 million in cash, cash equivalents, and investments; proforma cash of $201.4M with Oberland and COPIKTRA sales milestone ($15M), combined with expected product revenue and future tranche from

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Thu, 06 Aug 2026 16:01:00 -0400

AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $25.1 million
First patients dosed in all three TARGET-D Phase 2 registration-directed clinical trials evaluating VS-7375 across 2L PDAC, 2L/3L NSCLC, and 2L+ CRC
Updated clinical data for VS-7375 across pancreatic, lung, and colorectal cancers expected in October
Entered into a non-dilutive royalty financing agreement with Oberland Capital providing up to $75 million in cash, including $50 million at closing
Ended Q2 2026 with $136.4 million in cash, cash equivalents, and investments; proforma cash of $201.4M with Oberland and COPIKTRA sales milestone ($15M), combined with expected product revenue and future tranche from

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Thu, 06 Aug 2026 16:01:00 -0400

AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $25.1 million
First patients dosed in all three TARGET-D Phase 2 registration-directed clinical trials evaluating VS-7375 across 2L PDAC, 2L/3L NSCLC, and 2L+ CRC
Updated clinical data for VS-7375 across pancreatic, lung, and colorectal cancers expected in October
Entered into a non-dilutive royalty financing agreement with Oberland Capital providing up to $75 million in cash, including $50 million at closing
Ended Q2 2026 with $136.4 million in cash, cash equivalents, and investments; proforma cash of $201.4M with Oberland and COPIKTRA sales milestone ($15M), combined with expected product revenue and future tranche from

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Thu, 06 Aug 2026 16:01:00 -0400

AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $25.1 million
First patients dosed in all three TARGET-D Phase 2 registration-directed clinical trials evaluating VS-7375 across 2L PDAC, 2L/3L NSCLC, and 2L+ CRC
Updated clinical data for VS-7375 across pancreatic, lung, and colorectal cancers expected in October
Entered into a non-dilutive royalty financing agreement with Oberland Capital providing up to $75 million in cash, including $50 million at closing
Ended Q2 2026 with $136.4 million in cash, cash equivalents, and investments; proforma cash of $201.4M with Oberland and COPIKTRA sales milestone ($15M), combined with expected product revenue and future tranche from

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Thu, 06 Aug 2026 16:01:00 -0400

AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $25.1 million
First patients dosed in all three TARGET-D Phase 2 registration-directed clinical trials evaluating VS-7375 across 2L PDAC, 2L/3L NSCLC, and 2L+ CRC
Updated clinical data for VS-7375 across pancreatic, lung, and colorectal cancers expected in October
Entered into a non-dilutive royalty financing agreement with Oberland Capital providing up to $75 million in cash, including $50 million at closing
Ended Q2 2026 with $136.4 million in cash, cash equivalents, and investments; proforma cash of $201.4M with Oberland and COPIKTRA sales milestone ($15M), combined with expected product revenue and future tranche from

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Thu, 06 Aug 2026 16:01:00 -0400

AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $25.1 million
First patients dosed in all three TARGET-D Phase 2 registration-directed clinical trials evaluating VS-7375 across 2L PDAC, 2L/3L NSCLC, and 2L+ CRC
Updated clinical data for VS-7375 across pancreatic, lung, and colorectal cancers expected in October
Entered into a non-dilutive royalty financing agreement with Oberland Capital providing up to $75 million in cash, including $50 million at closing
Ended Q2 2026 with $136.4 million in cash, cash equivalents, and investments; proforma cash of $201.4M with Oberland and COPIKTRA sales milestone ($15M), combined with expected product revenue and future tranche from

Form 4 Verastem, Inc. For: Aug 03 Filed by: Paterson Dan

Wed, 05 Aug 2026 16:37:00 -0400
si-local-file:///var/storage/secattach/20260805/26875201.html

Form 4 Verastem, Inc. For: Aug 03 Filed by: Paterson Dan

Wed, 05 Aug 2026 16:37:00 -0400
si-local-file:///var/storage/secattach/20260805/26875201.html

Form SCHEDULE 13G Verastem, Inc. Filed by: VANGUARD CAPITAL MANAGEMENT LLC

Fri, 31 Jul 2026 10:46:00 -0400
si-local-file:///var/storage/secattach/20260731/26848438.html

Form SCHEDULE 13G Verastem, Inc. Filed by: VANGUARD CAPITAL MANAGEMENT LLC

Fri, 31 Jul 2026 10:46:00 -0400
si-local-file:///var/storage/secattach/20260731/26848438.html